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CASE REPORT
Warfarin-induced Skin Necrosis: Association with Heparin-induced
Thrombocytopenia and Protein S Deficiency
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Introduction significant risk factors, previous history or family his-
tory of thrombo-embolic disease. Initial laboratory
Warfarin is the most commonly used oral anti- findings included a white cell count of 11.5×109/l,
coagulant, not only for the prevention and treatment of Hb 7.8 g/dl, ESR 120 mm/h and C-reactive protein
venous thrombo-embolic disorders, but also in wider level of 300 (normal <5). Interestingly, her platelet
applications in cerebrovascular and peripheral arterial count at admission was 87×109/l, and subsequent
thromboprophylaxis. Although the problems as- platelet factor-4 antibody testing confirmed the pres-
sociated with the necessity for close monitoring of ence of HIT. Liver function tests demonstrated mild
anticoagulant status and the adverse effects of multiple elevation of the transaminase enzymes. Thrombophilia
drug interactions and haemorrhagic complications are screening identified a type III Protein S deficiency (low
well documented, the development of skin necrosis levels of free Protein S) with marginal elevation of
following introduction of warfarin is less common, anti-cardiolipin antibodies. However, Protein C and
affecting 0.01%–0.1% of patients.1,2 Similar syndromes anti-thrombin III levels were normal, Factor V Leiden
have been reported following administration of un- mutation was absent and screening for tumour
fractionated or low molecular weight heparin, and markers was negative.
may be related to the development of heparin-induced The patient commenced a danaparoid infusion and
thrombocytopenia (HIT) and its associated pro-throm- over the subsequent 10 days developed multiple vas-
botic state.1,3 culitic lesions on the contralateral limb associated with
recurrence of HIT. Platelet aggregation confirmed
cross-reactivity with danaparoid, and biopsy con-
firmed a leucocytoclastic vasculitis. All subsequentCase Report
screening for vasculitis, including anti-nuclear anti-
A 53-year-old woman presented with painful ec- bodies, rheumatoid factor, cryoglobulins, cold ag-
chymotic skin patches in the left thigh 5 days after glutinins, extractable nuclear antigen and hepatitis C
commencing warfarin therapy for an acute right limb were negative. The area of necrosis on the thigh became
ilio-femoral DVT. She had intravenous heparin ad- confluent and at surgical debridement was found to
ministered for 7 days prior to starting warfarin. Duplex involve full thickness skin and subcutaneous fat. The
scanning at this time confirmed the presence of ad- entire area was initially excised, and following a period
ditional left ilio-femoral DVT without evidence of of local dressings and further debridement, a split skin
vena cava involvement, and warfarin was ceased with graft was used to cover the defect with full healing
reinstitution of intravenous heparin. There were no over 3 weeks. After a short period on subcutaneous
enoxaparin (HIT antibodies did not cross react in the
presence of donor platelet and enoxaparin), warfarin
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Discussion unfractionated heparin, is an intensely pro-thrombotic
condition and has been associated with skin necrosis.2,3
Most patients who develop these lesions following theThe development of skin necrosis has been associated
introduction of warfarin have received initial treat-with the use of warfarin and, less frequently, with
ment with heparin (either unfractionated or low mo-heparin, usually occurring within the first 10 days of
lecular weight), and it is possible that the plateletinitiation, with the peak incidence being at 3–6 days.1,2,4
activation caused by HIT has contributed to, or caused,The vast majority of patients affected are women
the subsequent skin necrosis.over the age of 50 being treated for venous thrombo-
Reinstatement of warfarin following the de-embolism, and the typical area of distribution is in
velopment of skin necrosis, as in this case, has been askin overlying the fatty tissues such as the thigh,
generally accepted policy providing a smaller dosageabdomen, breast or buttocks. The lesions begin as
is used initially.4,5 In this case therapeutic enoxaparinpainful erythematous patches and often progress
coverage was added to provide outpatient anti-through an oedematous, bullous and haemorrhagic
coagulation and to prevent an abrupt fall in the Proteinstage to full thickness necrosis and eschar formation.
C level before a reduction in the levels of factors II,The aetiology of this complication is thought to be a
IX and X∗ caused by the re-introduction of warfarin.transient imbalance in the anticoagulant-procoagulant
From this case report we believe it is wise to in-proteins leading to a temporary hypercoagulable state
troduce warfarin gradually, especially in middle-aged,following the institution of warfarin therapy. The pro-
obese women treated for venous thrombo-embolismcess may be triggered by a rapid decrease in Protein
in order to avoid this rare, but limb- and sometimesC levels prior to the therapeutic decreases in factors
life-threatening complication.II, IX and X due to its shorter half life.1,2,4 Other authors
have suggested that drug interactions may displace
the protein-bound warfarin and affect its metabolism,
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